Body
The Max Näder Center for Rehabilitation Technologies and Outcomes Research is partnering with the biopharmaceutical company AbbVie to evaluate the potential of elezanumab, an investigational monoclonal antibody that may help in the treatment of spinal cord injury and other neurological conditions. The pilot study will involve testing optimal biosensor placement to capture surface electromyography (sEMG), among other assessments. Read the full press release here.